294 related articles for article (PubMed ID: 37460004)
1. Recent advances in the management and implementation of care for familial hypercholesterolaemia.
Lan NSR; Bajaj A; Watts GF; Cuchel M
Pharmacol Res; 2023 Aug; 194():106857. PubMed ID: 37460004
[TBL] [Abstract][Full Text] [Related]
2. Reducing cardiovascular risk in patients with familial hypercholesterolemia: Risk prediction and lipid management.
Miname MH; Santos RD
Prog Cardiovasc Dis; 2019; 62(5):414-422. PubMed ID: 31669498
[TBL] [Abstract][Full Text] [Related]
3. Novel therapies for familial hypercholesterolemia.
Mohamed F; Seedat F; Raal FJ
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin type 9.
Page MM; Stefanutti C; Sniderman A; Watts GF
Clin Sci (Lond); 2015 Jul; 129(1):63-79. PubMed ID: 25881720
[TBL] [Abstract][Full Text] [Related]
5. How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment.
van den Bosch SE; Corpeleijn WE; Hutten BA; Wiegman A
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980941
[TBL] [Abstract][Full Text] [Related]
6. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
Agabiti Rosei E; Salvetti M
High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):217-30. PubMed ID: 27567901
[TBL] [Abstract][Full Text] [Related]
7. Homozygous familial hypercholesterolemia: what treatments are on the horizon?
Bajaj A; Cuchel M
Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430
[TBL] [Abstract][Full Text] [Related]
8. Familial Hypercholesterolemia: Challenges for a High-Risk Population: JACC Focus Seminar 1/3.
Choi D; Malick WA; Koenig W; Rader DJ; Rosenson RS
J Am Coll Cardiol; 2023 Apr; 81(16):1621-1632. PubMed ID: 37076217
[TBL] [Abstract][Full Text] [Related]
9. Homozygous familial hypercholesterolaemia: update on management.
France M
Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
[TBL] [Abstract][Full Text] [Related]
10. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
[TBL] [Abstract][Full Text] [Related]
12. Real-life LDL-C treatment goals achievement in patients with heterozygous familial hypercholesterolemia in the Czech Republic and Slovakia: Results of the PLANET registry.
Vrablik M; Raslová K; Vohnout B; Blaha V; Satny M; Kyselak O; Vaclova M; Urbanek R; Maskova J; Soska V; Freiberger T
Atherosclerosis; 2018 Oct; 277():355-361. PubMed ID: 30270071
[TBL] [Abstract][Full Text] [Related]
13. Long term follow-up of genetically confirmed patients with familial hypercholesterolemia treated with first and second-generation statins and then with PCSK9 monoclonal antibodies.
Pasta A; Cremonini AL; Formisano E; Fresa R; Bertolini S; Pisciotta L
Atherosclerosis; 2020 Sep; 308():6-14. PubMed ID: 32771803
[TBL] [Abstract][Full Text] [Related]
14. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.
Bajaj A; Cuchel M
J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Ridker PM; Rose LM; Kastelein JJP; Santos RD; Wei C; Revkin J; Yunis C; Tardif JC; Shear CL;
J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
[TBL] [Abstract][Full Text] [Related]
16. Familial Hypercholesterolemia: Global Burden and Approaches.
Tokgozoglu L; Kayikcioglu M
Curr Cardiol Rep; 2021 Sep; 23(10):151. PubMed ID: 34480646
[TBL] [Abstract][Full Text] [Related]
17. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
Robinson JG
J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
[TBL] [Abstract][Full Text] [Related]
18. PCSK9 inhibition in the management of familial hypercholesterolemia.
Ogura M
J Cardiol; 2018 Jan; 71(1):1-7. PubMed ID: 28784313
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.
Pirillo A; Catapano AL; Norata GD
Curr Atheroscler Rep; 2021 Oct; 23(12):79. PubMed ID: 34698927
[TBL] [Abstract][Full Text] [Related]
20. Subclinical coronary atherosclerosis and cardiovascular risk stratification in heterozygous familial hypercholesterolemia patients undergoing statin treatment.
Miname MH; Bittencourt MS; Nasir K; Santos RD
Curr Opin Lipidol; 2019 Apr; 30(2):82-87. PubMed ID: 30649025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
